Introduction {#Sec1}
============

Acute myocardial infarction (AMI), a serious form of coronary artery disease (CAD), is a significant cause of death worldwide, particularly in the elderly population \[[@CR1]\]. Actually, the elderly AMI patients who may have poor prognosis could be greatly improved by timely and appropriate intervention measures \[[@CR2]\]. Based on this, the discovery of prognosis-related biomarkers could benefit considerably to the oriented treatment and the prognostic evaluation in coronary infarction \[[@CR3]--[@CR5]\]. Thus, to find an efficient predictor is urgently needed.

Nowadays, the general public have more in-depth understanding of the correlation between serum lipid level and CAD \[[@CR6]\]. In addition, as for single lipids, some lipid ratios could be well applied to predict CAD and the associations were of comparable magnitude \[[@CR7]\]. For instance, the ratio of monocyte to high-density lipoprotein cholesterol (HDL-C) (MHR) \[[@CR8], [@CR9]\] and the ratio of low-density lipoprotein cholesterol (LDL-C) to HDL-C (LDL-C/HDL-C) were found to have correlation with poor prognosis in cardiovascular diseases \[[@CR10], [@CR11]\].

It was showed that the inflammation and the abnormal lipid metabolism took a critical part in plaque formation and atherosclerosis in the development of AMI \[[@CR12]--[@CR15]\]. Circulating neutrophils played a causative role in the immuno-inflammatory responses of the pathogenesis of atherosclerosis \[[@CR16]\]. Neutrophils abundance was strongly connected with the incidence of cardiac adverse events \[[@CR17]\]. On the contrary, recent investigations suggested that the HDL-C was inversely related to the risk of CAD and could be highly predictive of its prognosis \[[@CR18]\]. What's more, previous clinical and experimental studies indicated that HDL could regulate the function of activated neutrophils \[[@CR19]\]. In contrast, activated neutrophils could also affect the composition and function of HDL \[[@CR20]\]. Therefore, we hypothesized that the neutrophil to HDL-C ratio (NHR), a potential new lipid biomarker, might reflect the inflammation level and the lipid profile in a quantitative manner. With these considerations, our work was conducted to compare the predictive value of NHR with other two hematological parameters (including MHR and LDL-C/HDL-C) in elderly AMI patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

In current work, the data of 528 patients (65--85 years) with AMI in the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2016 and December 2017 were collected. Permission to accomplish the study was received from the institutional board review committee (TJ-C20141112). This study followed the principles of the Declaration Helsinki.

In our study, the patients were admitted with AMI within 1 month of symptom onset. The eligible population corresponding to AMI diagnosis standards mainly included the patients who was defined as ST-segment elevation myocardial infarction (STEMI, typical symptoms of myocardial ischemia lasting for \> 30 min, with ST-segment elevation \> 1 mm in ≥2 contiguous leads and/or new onset of left bundle branch block) \[[@CR21]\] and without ST-segment elevation myocardial infarction (NSTEMI, a rise of myocardial injury markers in combination with typical symptoms of myocardial ischemia and without ST-segment elevation) \[[@CR22]\].

Here were the exclusion criteria. (1) Patients who were younger than 65 or older than 85 years. (2) Patients who had sepsis or trauma. (3) Patients who were diagnosed as active cancer, hematological proliferative diseases, autoimmune diseases, pulmonary arterial hypertension, end-stage liver disease or renal failure. (4) Patients who took medications including any steroid therapy or chemotherapy around the diagnosis period, thrombolytic therapy and glycoprotein IIb/IIIa inhibitors.

Clinical data collection {#Sec4}
------------------------

Current study evaluated the demographic data from medical records including age, sex, smoking status, and the anamnesis (such as the history of CAD, hypertension, diabetes and cerebrovascular diseases). We collected the vital signs (heart rate, systolic blood pressure, diastolic blood pressure) and Killip class at admission. Besides, the data of pharmacotherapy during hospitalization were included as well.

In all the patients, a routine blood test was performed immediately after admission. Laboratory results included complete blood cell counts (white blood count \[WBC\] and its subtypes, hemoglobin), aminopherase, creatinine, serum lipid (triglycerides, total cholesterol, LDL-C, HDL-C), N-terminal prohormone of brain natriuretic peptide, and myocardial injury markers. Also, we gathered the result of left ventricular ejection fraction (LVEF) from cardiac ultrasonography.

Coronary angiography (CAG) {#Sec5}
--------------------------

The CAG was performed based on the actual clinical situation and the results were determined by two professional cardiovascular physicians. Based on the clinical findings, physicians would select different treatment strategies (such as percutaneous coronary intervention \[PCI\], coronary artery bypass grafting \[CABG\], and medical therapy) in the light of corresponding practice guidelines \[[@CR23]\]. Furthermore, we also collected data of thrombolysis in myocardial infarction trial (TIMI) blood flow grade and Gensini score (an angiographic scoring system assessed the severity of a coronary artery) from the electronic medical records database.

Clinical follow-up and study end points {#Sec6}
---------------------------------------

The endpoints of present study were all-cause mortality and recurrent myocardial infarction (RMI) that happened during the follow-up period. All-cause mortality was defined as death from any cause. RMI was defined as recurrence of AMI whether the reinfarction area located in the original or other site \[[@CR24]\]. Follow-up of all patients were began from the first day after discharge until December 2018. The access to information during follow-up was performed through standard telephone interview with patients or their relatives at regular intervals.

Statistical analysis {#Sec7}
--------------------

NHR, MHR and LDL-C/HDL-C were calculated by the formula respectively: NHR = neutrophil / HDL, MHR = monocyte / HDL and LDL-C/HDL-C = LDL-C / HDL-C. In baseline characteristics analysis, continuous variables were presented as mean ± standard error and tested for normal distribution by the Kolmogorov-Smirnov test. For the comparison of variables between groups, the parametric/nonparametric tests (continuous variables) or Chi-square test (categorical variables) was selected according to the type of variables. Using Receiver operating characteristic (ROC) curves to find out the optimal cutoff points of NHR, MHR and LDL-C/HDL-C. Kaplan-Meier curve for survival analysis was plotted to assess the prognosis between index-determined subgroups with log-rank test. The Spearman correlation coefficient was computed to calculate the correlation between two variables. Univariate analyses were performed to determine the significance of prognostic variables. Any variables examined in the univariate analysis for which the *P* \< 0.10 or several conventional risk factors for AMI (such as age, gender, smoking status, and previous history of CAD, hypertension, diabetes) were contained in the forward stepwise multivariate model. A value of *P* \< 0.05 was supposed to be statistically significant. All statistical analyses were performed using SPSS Version 22.0.

Results {#Sec8}
=======

ROC curve analysis {#Sec9}
------------------

ROC curve was analyzed in search of the cutoff value of NHR, MHR and LDL-C/HDL-C for the evaluation of long-term clinical outcomes in elderly AMI patients. All of these results were presented in Fig. [1](#Fig1){ref-type="fig"}. For NHR, the area under the curve (AUC) was 0.69 (*P* \< 0.001, 95% confidence interval \[CI\]: 0.63 to 0.76). The cutoff point was observed at 5.74, with a sensitivity of 77.60% and a specificity of 50.80%. (Fig. [1](#Fig1){ref-type="fig"}a). Accordingly, the AUC for MHR was calculated as 0.60 (*P* = 0.004, 95% CI: 0.53 to 0.68; Fig. [1](#Fig1){ref-type="fig"}b). The cutoff value for MHR was found to be 0.67, with a sensitivity of 47.40% and a specificity of 73.40%. Moreover, the AUC for LDL-C/HDL-C was 0.59 (*P* = 0.017, 95% CI: 0.51 to 0.66) with a cutoff point at 3.57 (sensitivity 34.20%, specificity 85.30%; Fig. [1](#Fig1){ref-type="fig"}c). Consequently, the AUC for NHR was larger than those for MHR and LDL-C/HDL-C and it preliminarily presented better predictive value for the prognosis in elderly AMI patients. Fig. 1ROC curve analysis for NHR, MHR and LDL-C/HDL-C (**a, b, c**). **a** The AUC for NHR was 0.69 (*P* \< 0.001), and the cutoff point was 5.74, with a sensitivity of 77.60% and a specificity of 50.80%. **b** The AUC for MHR was 0.60 (*P* = 0.004), and the cutoff point was 0.67, with a sensitivity of 47.40% and a specificity of 73.40%. **c** The AUC for LDL-C/HDL-C was 0.59 (*P* = 0.017), and the cutoff point was 3.57, with a sensitivity of 34.20% and a specificity of 85.30%. ROC, receiver operating characteristic. AUC, area under the curve. NHR, neutrophil to high-density lipoprotein cholesterol ratio. MHR, monocyte to high-density lipoprotein cholesterol ratio. LDL-C/HDL-C, low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

Baseline characteristics {#Sec10}
------------------------

As shown in Table [1](#Tab1){ref-type="table"}, the total number of 528 patients were collected and grouped by cutoff points as described above. 333 of the 528 patients were male (63.07%) and the population were aged between 65 and 85 years old (72.66 ± 0.23). Diagnoses included: 268 patients with STEMI and 260 patients with NSTEMI. Table 1Baseline characteristics of elderly AMI patientsVariableNHR \< 5.74NHR ≥ 5.74*P*MHR \< 0.67MHR ≥ 0.67*P*LDL-C/HDL-C \< 3.57LDL-C/HDL-C ≥ 3.57*Pn* = 249*n* = 279*n* = 367*n* = 161*n* = 439*n* = 89Age, year72.54 ± 0.3472.76 ± 0.320.55572.35 ± 0.2773.36 ± 0.420.04872.60 ± 0.2572.93 ± 0.560.754Gender (male), n (%)150 (60.24%)183 (65.59%)0.203206 (56.13%)127 (78.89%)\< 0.001271 (61.73%)62 (69.66%)0.157Smoking status, n (%)92 (36.95%)118 (42.29%)0.210134 (36.51%)76 (47.20%)0.021167 (38.04%)43 (48.31%)0.071Hypertension, n (%)144 (57.83%)169 (60.57%)0.522215 (58.58%)98 (60.87%)0.623267 (60.82%)46 (51.69%)0.110Prior CAD, n (%)40 (16.06%)30 (10.75%)0.07250 (13.62%)20 (12.42%)0.70860 (13.67%)10 (11.24%)0.537Diabetes, n (%)51 (20.48%)86 (30.82%)0.00794 (25.61%)43 (26.71%)0.792112 (25.51%)25 (28.09%)0.613CVD, n (%)33 (13.25%)39 (13.98%)0.80851 (13.90%)21 (13.04%)0.79359 (13.44%)13 (14.61%)0.770SBP on admission (mmHg)132.81 ± 1.50128.10 ± 1.490.013131.50 ± 1.31127.65 ± 1.770.073130.14 ± 1.15131.25 ± 2.750.854DBP on admission (mmHg)75.65 ± 0.8475.61 ± 0.940.92776.31 ± 0.7674.07 ± 1.140.04275.69 ± 0.6975.34 ± 1.630.733HR on admission (beats/min)74.56 ± 0.9380.35 ± 0.96\< 0.00176.44 ± 0.8080.31 ± 1.290.02377.11 ± 0.7480.13 ± 1.780.364Hospitalization day7.56 ± 0.368.99 ± 0.450.0137.99 ± 0.319.06 ± 0.660.4668.08 ± 0.319.47 ± 0.850.290Diagnosis, n (%) STEMI98 (39.36%)170 (60.93%)\< 0.001181 (49.32%)87 (54.04%)0.318216 (49.20%)52 (58.43%)0.112 NSTEMI151 (60.64%)109 (39.07%)\< 0.001186 (50.68%)74 (45.96%)0.318223 (50.80%)37 (41.57%)0.112 Killip class, III-IV, n (%)41 (16.47%)60 (21.51%)0.14261 (16.62%)40 (24.84%)0.02781 (18.45%)20 (22.47%)0.379 LVEF, %53.72 ± 0.7850.45 ± 0.750.00152.85 ± 0.6150.02 ± 1.110.04251.93 ± 0.6152.27 ± 1.230.464 Creatinine (μmol/L)84.54 ± 1.7095.13 ± 2.13\< 0.00187.59 ± 1.7195.94 ± 2.34\< 0.00188.89 ± 1.4796.29 ± 4.010.169 AST (u/L)56.61 ± 4.44119.89 ± 7.63\< 0.00192.17 ± 6.0985.22 ± 7.040.37389.69 ± 4.9791.84 ± 13.880.584 ALT (u/L)29.47 ± 1.7243.56 ± 2.76\< 0.00134.27 ± 1.7242.94 ± 3.910.00436.85 ± 1.9437.22 ± 3.150.904 NT-proBNP (pg/mL)4815.92 ± 560.615601.26 ± 538.240.0574934.39 ± 467.275906.79 ± 697.260.0085204.51 ± 431.335316.10 ± 888.550.287 CTnI (pg/mL)9435.84 ± 911.2120,906.32 ± 1202.02\< 0.00114,994.50 ± 975.9116,642.27 ± 1426.500.09415,550.19 ± 880.7115,234.31 ± 2005.530.918 HDL-C (mmol/L)1.30 ± 0.040.98 ± 0.02\< 0.0011.24 ± 0.030.89 ± 0.02\< 0.0011.19 ± 0.020.84 ± 0.02\< 0.001 LDL-C (mmol/L)2.55 ± 0.062.66 ± 0.060.3122.69 ± 0.052.43 ± 0.070.0042.41 ± 0.043.62 ± 0.10\< 0.001 Total triglyceride (mmol/L)1.36 ± 0.071.42 ± 0.070.1131.33 ± 0.061.53 ± 0.100.0121.36 ± 0.061.55 ± 0.090.002 Total cholesterol (mmol/L)4.10 ± 0.074.14 ± 0.070.6934.25 ± 0.063.84 ± 0.08\< 0.0013.95 ± 0.054.98 ± 0.12\< 0.001 WBC count (10^9^/L)6.72 ± 0.1311.10 ± 0.21\< 0.0018.30 ± 0.1710.72 ± 0.31\< 0.0018.97 ± 0.179.38 ± 0.380.780 Platelet count (10^9^/L)191.70 ± 3.82212.31 ± 4.01\< 0.001200.59 ± 3.32207.16 ± 5.270.379200.23 ± 3.06214.22 ± 7.080.372 Neutrophil count (10^9^/L)4.56 ± 0.119.19 ± 0.21\< 0.0016.36 ± 0.178.47 ± 0.33\< 0.0016.98 ± 0.187.14 ± 0.370.357 Lymphocyte count (10^9^/L)1.40 ± 0.041.37 ± 0.040.1421.32 ± 0.031.53 ± 0.060.0021.37 ± 0.031.47 ± 0.080.809 Monocyte count (10^9^/L)0.45 ± 0.010.65 ± 0.02\< 0.0010.43 ± 0.010.84 ± 0.02\< 0.0010.55 ± 0.010.57 ± 0.030.145 Hemoglobin (mg/dL)126.65 ± 1.19125.87 ± 1.100.536126.88 ± 0.95124.78 ± 1.530.297126.02 ± 0.86127.34 ± 2.260.922Medications in hospital, n (%) Antiplatelet therapy243 (97.59%)271 (97.13%)0.744361 (98.37%)153 (95.03%)0.051427 (97.27%)87 (97.75%)0.003 Beta-blocker182 (73.09%)198 (70.97%)0.587271 (73.84%)109 (67.70%)\< 0.001317 (72.21%)63 (70.79%)0.237 ACEI/ARB191 (76.71%)187 (67.03%)0.014271 (73.84%)107 (66.46%)0.083318 (72.44%)60 (67.42%)0.596 Statin247 (99.20%)275 (98.57%)0.915364 (99.18%)158 (98.14%)0.297434 (98.86%)88 (98.88%)0.002Long-term clinical events, n (%) Long-term mortality17 (6.83%)59 (21.15%)\< 0.00140 (10.90%)36 (22.36%)0.00150 (11.39%)26 (29.21%)\< 0.001 Long-term RMI10 (4.02%)31 (11.11%)0.00222 (5.99%)19 (11.80%)0.02229 (6.61%)12 (13.48%)0.010*AMI* acute myocardial infarction, *NHR* neutrophil to high-density lipoprotein cholesterol ratio, *MHR* monocyte to high-density lipoprotein cholesterol ratio, *LDL-C/HDL-C* low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, *CAD* coronary artery disease, *CVD* cerebrovascular diseases, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HR* heart rate, *STEMI* ST-segment elevation myocardial infarction, *NSTEMI* non-ST-elevation myocardial infarction, *LVEF* left ventricular ejection fraction, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *NT-proBNP* N-terminal pro-brain natriuretic peptide, *CTnI* cardiac troponin I, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *WBC* white blood cell, *ACEI/ARB* angiotensin-converting enzyme inhibitor/ angiotensin II receptor blocker, *RMI* recurrent myocardial infarctionData presented are mean ± SEM or n(%)

In the groups divided by the NHR \< 5.74 and NHR ≥ 5.74, results showed that there were clinically statistical differences among two groups in terms of medical history of diabetes (*P* = 0.007), vital signs at admission (*P* = 0.013; *P* \< 0.001), LVEF (*P* = 0.001). Elevated level of NHR was associated with increased WBC and its subtypes (*P* \< 0.001, respectively), so was in platelet count (*P* \< 0.001), but not with lymphocyte count (*P* = 0.142) and hemoglobin (*P* = 0.536). Moreover, patients in NHR ≥ 5.74 were more likely to have worse hepatorenal function (*P* ≤ 0.001, respectively) and decreased concentration of HDL-C (*P* \< 0.001).

In the groups divided by the MHR \< 0.67 and MHR ≥ 0.67, it was noted that there were statistic differences in age (*P* = 0.048), gender (*P* \< 0.001), smoking status (*P* = 0.021), the function index of heart and liver and kidney and the level of serum lipid as well as the complete blood counts (*P* \< 0.050, respectively). In terms of the data grouped by the cut-off point of LDL-C/HDL-C, no statistically significant between-group differences for the primary outcomes were detected, except for the level of serum lipids (*P* \< 0.001, *P* \< 0.001, *P* \< 0.001, *P* = 0.002, respectively).

The angiographic characteristics were reported in Table [2](#Tab2){ref-type="table"}. When grouping by NHR, no significant differences were discovered in the culprit vessel location and the CABG therapy, except for the culprit vessel quantity (*P* \< 0.001), onset to reperfusion time (*P* \< 0.001), tirofiban use (*P* = 0.038), stent use (*P* = 0.030), thrombus aspiration use (*P* = 0.001), the multi-vessel PCI therapy (*P* = 0.006), the TIMI grade (*P* \< 0.001) and Gensini score (*P* = 0.003). In the groups divided by the MHR \< 0.67 and MHR ≥ 0.67, it was resulted that the CAG outcomes were worse in the high-risk group. What's more, it was the same in the LDL-C/HDL-C grouping. Table 2Angiographic and procedural characteristics in the study populationVariableNHR \< 5.74NHR ≥ 5.74*P*MHR \< 0.67MHR ≥ 0.67*P*LDL-C/HDL-C \< 3.57LDL-C/HDL-C ≥ 3.57*Pn* = 249*n* = 279*n* = 367*n* = 161*n* = 439*n* = 89Culprit vessel, n (%) LAD175 (70.28%)216 (77.42%)0.062273 (74.39%)118 (73.29%)\< 0.001325 (74.03%)66 (74.16%)0.980 LCX128 (51.41%)160 (57.35%)0.171193 (52.59%)95 (59.01%)0.173234 (53.30%)54 (60.67%)0.203 RCA130 (52.21%)167 (59.86%)0.077209 (56.95%)88 (54.66%)0.625245 (55.81%)52 (58.43%)0.650No. of diseased vessels, n (%)\< 0.001\< 0.001\< 0.001 155 (22.09%)67 (24.01%)95 (25.89%)27 (16.77%)105 (23.92%)17 (19.10%) 260 (24.10%)70 (25.09%)86 (23.43%)44 (27.33%)105 (23.92%)25 (28.09%) 387 (34.94%)112 (40.14%)137 (37.33%)62 (38.51%)163 (37.13%)35 (39.33%)Onset to reperfusion time, h16.43 ± 0.5612.95 ± 0.54\< 0.00114.66 ± 0.4614.45 ± 0.750.69814.67 ± 0.4314.24 ± 0.980.443Tirofiban use, n (%)170 (68.27%)213 (76.34%)0.038276 (75.20%)107 (66.46%)0.038321 (73.12%)62 (69.66%)0.505Stent use, n (%)146 (58.63%)189 (67.74%)0.030242 (65.94%)93 (57.76%)0.072279 (63.55%)55 (61.80%)0.754Use of thrombus aspiration, n (%)8 (3.21%)29 (10.39%)0.00130 (8.17%)8 (4.97%)0.18930 (6.83%)7 (7.87%)0.728Multi-vessel PCI therapy, n (%)201 (80.72%)249 (89.25%)0.006317 (86.38%)133 (82.61%)0.261373 (84.97%)77 (86.52%)0.707CABG therapy, n (%)21 (8.43%)17 (6.09%)0.29925 (6.81%)14 (8.70%)0.44629 (6.61%)9 (10.11%)0.243Preprocedural TIMI grade, n (%):\< 0.001\< 0.001\< 0.001 0118 (47.39%)181 (64.87%)206 (56.13%)93 (57.76%)242 (55.13%)58 (65.17%) 173 (29.32%)64 (22.94%)101 (27.52%)36 (22.36%)119 (27.11%)18 (20.22%) 29 (3.61%)3 (1.08%)10 (2.72%)3 (1.86%)11 (2.51%)1 (1.12%) 30 (0.00%)1 (0.36%)0 (0.00%)1 (0.62%)1 (0.23%)0 (0.00%)Postprocedural TIMI grade, n (%):\< 0.001\< 0.001\< 0.001 031 (12.45%)34 (12.19%)93 (25.34%)50 (31.06%)50 (11.39%)16 (17.98%) 114 (5.62%)18 (6.45%)22 (5.99%)10 (6.21%)27 (6.15%)5 (5.62%) 28 (3.21%)7 (2.51%)12 (3.27%)3 (1.86%)15 (3.42%)0 (0.00%) 3148 (59.44%)189 (67.74%)240 (65.40%)98 (60.87%)281 (64.01%)56 (62.92%)Gensini score70.92 ± 3.6184.78 ± 3.350.00378.60 ± 3.0677.43 ± 4.130.66275.45 ± 2.6692.03 ± 6.340.005*NHR* neutrophil to high-density lipoprotein cholesterol ratio, *MHR* monocyte to high-density lipoprotein cholesterol ratio, *LDL-C/HDL-C* low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, *LAD* left coronary artery, *LCX* left circumflex, *RCA* right coronary artery, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIMI* thrombolysis in myocardial infarctionData presented are mean ± SEM or n(%)

Survival analysis {#Sec11}
-----------------

The Kaplan-Meier Curve were plotted with the event-free surival data from the follow-up. Mean duration of follow-up was 673.85 ± 14.32 days (median 679.50 days). The long-term mortality in the high-risk groups were significantly higher than low-risk groups (log-rank tests: all *P* \< 0.001, Fig. [2](#Fig2){ref-type="fig"}a-c). As shown in Fig. [2](#Fig2){ref-type="fig"}d-f, it was indicated that patients in the high-risk groups had significantly worse long-term RMI than patients in the low-risk groups (log-rank tests: *P* = 0.002, *P* = 0.010, *P* = 0.023, respectively). Fig. 2Kaplan-Meier survival curves for long-term mortality and RMI according to the NHR, MHR and LDL-C/HDL-C (**a, b, c, d, e, f**). **a** Kaplan-Meier survival curves of long-term mortality according to NHR (log-rank test: *P* \< 0.001). **b** Kaplan-Meier survival curves of long-term mortality according to MHR (log-rank test: *P* \< 0.001). **c** Kaplan-Meier survival curves of long-term mortality according to LDL-C/HDL-C (log-rank test: *P* \< 0.001). **d** Kaplan-Meier survival curves of long-term RMI according to NHR (log-rank test: *P* = 0.002). **e** Kaplan-Meier survival curves of long-term RMI according to MHR (log-rank test: *P* = 0.010). **f** Kaplan-Meier survival curves of long-term RMI according to LDL-C/HDL-C (log-rank test: *P* = 0.023). RMI, recurrent myocardial infarction. NHR, neutrophil to high-density lipoprotein cholesterol ratio. MHR, monocyte to high-density lipoprotein cholesterol ratio. LDL-C/HDL-C, low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

Univariate and multivariate cox regression analyses {#Sec12}
---------------------------------------------------

In multivariate regression analysis, Gensini score (hazard ratio \[HR\]: 1.00, 95% CI: 1.00 to 1.01, *P* = 0.034), Killip class (HR: 1.85, 95% CI: 1.48 to 2.31, *P* \< 0.001), WBC (HR:1.09, 95% CI: 1.03 to 1.16, *P* = 0.005), hemoglobin (HR: 0.98, 95% CI: 0.97 to 0.99, *P* = 0.001) and the NHR (HR: 1.96, 95% CI: 1.02 to 3.75, *P* = 0.044) were found as independent predictors of long-term mortality, but not with MHR (*P* = 0.237) or LDL-C/HDL-C (*P* = 0.092) (Table [3](#Tab3){ref-type="table"}). Moreover, for predicting long-term RMI, we found that NHR (HR: 2.23, 95% CI: 1.04 to 4.79, *P* = 0.040) was still the potential predictor along with gender (HR: 2.27, 95% CI: 1.22 to 4.23, *P* = 0.010), Killip class (HR: 1.69, 95% CI: 1.23 to 2.33, *P* = 0.001) and monocyte (HR: 3.47, 95% CI: 1.46 to 8.26, *P* = 0.005), but not with MHR (*P* = 0.505) and LDL-C/HDL-C (*P* = 0.248) (Table [4](#Tab4){ref-type="table"}). Table 3Predictors of long-term mortality in univariable and multivariable Cox regression analysesVariablesUnivariableMultivariableHazard ratio (95% CI)*P*Hazard ratio (95% CI)*P*Age, year1.09 (1.04 to 1.13)\< 0.001--0.268Gender (male)1.73 (1.10 to 2.71)0.017--0.066Gensini score1.01 (1.00 to 1.01)0.009**1.00 (1.00 to 1.01)0.034**Smoking status1.53 (0.94 to 2.50)0.087--0.814Hypertension1.09 0.69 to 1.73)0.703--0.877Prior CAD1.47 (0.82 to 2.62)0.196--0.245Diabetes1.85 (1.17 to 2.94)0.009--0.225Killip class2.14 (1.73 to 2.64)\< 0.001**1.85 (1.48 to 2.31)\< 0.001**LVEF0.97 (0.95 to 0.98)\< 0.001--0.274CTnI1.97 (1.26 to 3.09)0.003--0.333WBC1.16 (1.11 to 1.23)\< 0.001**1.09 (1.03 to 1.16)0.005**Neutrophil1.17 (1.11 to 1.22)\< 0.001--0.866Lymphocyte0.89 (0.62 to 1.26)0.499Monocyte2.84 (1.50 to 5.37)0.001--0.496Platelet1.00 (1.00 to 1.01)0.102Hemoglobin0.98 (0.97 to 0.99)\< 0.001**0.98 (0.97 to 0.99)0.001**Total cholesterol1.12 (0.93 to 1.35)0.246Total triglyceride0.95 (0.76 to 1.18)0.628HDL-C0.64 (0.35 to 1.16)0.139LDL-C1.18 (0.95 to 1.48)0.130Creatinine1.01 (1.01 to 1.02)\< 0.001--0.207NHR ≥ 5.743.21 (1.87 to 5.50)\< 0.001**1.96 (1.02 to 3.75)0.044**MHR ≥ 0.672.22 (1.42 to 3.49)0.001--0.237LDL-C/HDL-C ≥ 3.571.25 (1.59 to 4.11)0.010--0.092*CI* confidence interval, *CAD* coronary artery disease, *LVEF* left ventricular ejection fraction, *CTnI* cardiac troponin I, *WBC* white blood cell, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *NHR* neutrophil to high-density lipoprotein cholesterol ratio, *MHR* monocyte to high-density lipoprotein, *LDL-C/HDL-C* low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratioNote: Bolded differences show statistical difference at the *p* \< 0.05 for multivariate analysisTable 4Predictors of long-term RMI in univariable and multivariable Cox regression analysesVariablesUnivariableMultivariableHazard ratio (95% CI)*P*Hazard ratio (95% CI)*P*Age, year1.06 (1.01 to 1.13)0.028--0.275Gender (male)2.15 (1.16 to 3.92)0.015**2.27 (1.22 to 4.23)0.010**Gensini score1.01 (1.00 to 1.01)0.046--0.104Smoking status1.46 (0.75 to 2.81)0.263--0.753Hypertension1.00 (0.54 to 1.87)0.990--0.992Prior CAD1.95 (0.60 to 6.33)0.265--0.401Diabetes2.18 (1.17 to 4.05)0.014--0.240Killip class1.73 (1.28 to 2.34)\< 0.001**1.69 (1.23 to 2.33)0.001**LVEF0.97 (0.95 to 1.00)0.026--0.837CTnI1.86 (1.01 to 3.43)0.048--0.236WBC1.15 (1.07 to 1.24)\< 0.001--0.554Neutrophil1.14 (1.07 to 1.23)\< 0.001--0.797Lymphocyte0.78 (0.47 to 1.30)0.342Monocyte4.31 (1.93 to 9.58)\< 0.001**3.47 (1.46 to 8.26)0.005**Platelet1.01 (1.00 to 1.01)0.009--0.075Hemoglobin0.98 (0.97 to 1.00)0.012--0.089Total cholesterol1.21 (0.95 to 1.56)0.126Total triglyceride1.02 (0.79 to 1.31)0.906HDL-C0.94 (0.49 to 1.81)0.845LDL-C1.25 (0.94 to 1.67)0.122Creatinine1.01 (1.00 to 1.02)0.049--0.276NHR ≥ 5.742.98 (1.46 to 6.08)0.003**2.23 (1.04 to 4.79)0.040**MHR ≥ 0.672.20 (1.19 to 4.07)0.012--0.505LDL-C/HDL-C ≥ 3.572.14 (1.09 to 4.20)0.027--0.248*RMI* recurrent myocardial infarction, *CI* confidence interval, *CAD* coronary artery disease, *LVEF* left ventricular ejection fraction, *CTnI* cardiac troponin I, *WBC* white blood cell, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *NHR* neutrophil to high-density lipoprotein cholesterol ratio, *MHR* monocyte to high-density lipoprotein cholesterol ratio, *LDL-C/HDL-C* low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratioNote: Bolded differences show statistical difference at the p \< 0.05 for multivariate analysis

Correlation analysis between lipid ratios and Gensini score {#Sec13}
-----------------------------------------------------------

As shown in Fig. [3](#Fig3){ref-type="fig"}, a weak but significant positive correlation between NHR and Gensini score in our population (*r* = 0.15, *P* \< 0.001; Fig. [3](#Fig3){ref-type="fig"}a), so was in LDL-C/HDL-C (*r* = 0.12, *P* = 0.007; Fig. [3](#Fig3){ref-type="fig"}c). It was found that there was no correlation between MHR and Gensini score (*r* = 0.05, *P* = 0.259; Fig. [3](#Fig3){ref-type="fig"}b). Fig. 3Correlation between lipid ratios (NHR, MHR and LDL-C/HDL-C) and Gensini score in AMI patients (**a, b, c**). **a.** There was a positive correlation between NHR and Gensini score: *r* = 0.15, *P* \< 0.001. **b.** There was no correlation between MHR and Gensini score: *r* = 0.05, *P* = 0.259. **c.** There was a positive correlation between LDL-C/HDL-C and Gensini score: *r* = 0.12, *P* = 0.007. AMI, acute myocardial infarction. NHR, neutrophil to high-density lipoprotein cholesterol ratio. MHR, monocyte to high-density lipoprotein cholesterol ratio. LDL-C/HDL-C, low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

Discussion {#Sec14}
==========

In our work, our results presented that higher level of NHR was associated with higher risk of long-term mortality and RMI. NHR has a superior prognostic value for long-term clinical outcomes in elderly patients compared with MHR and LDL-C/HDL-C. Moreover, there was a positive correlation between NHR and the severity of a coronary artery. This study appears to be novel to assess the prognostic role of NHR for long-term outcomes in elderly AMI patients. The results of present study mainly applied to patients aged between 65 and 85 years.

Recent studies have payed more attentions to the linkage between lipid-related biomarkers and cardiac disease. Previous studies reported that the elevated MHR has greater risk of the worse prognosis in AMI \[[@CR25]--[@CR27]\]. Besides, in a prospective cohort study, the high level of LDL-C/HDL-C was discovered to be related with an increased risk of adverse cardiovascular events \[[@CR28]\]. From the survival analysis, our results were consistent with previous studies. Actually, the etiology of AMI was complicated, included alternated lipid metabolism, inflammatory reaction, oxidation injury, and other pathological processes \[[@CR29]--[@CR32]\]. Herein, we hypothesized that the NHR, a novel index composed of inflammatory cell and lipid cholesterol, might reflect the inflammatory status and the lipid metabolism more comprehensively. In the present study, the prediction abilities of NHR and other two existing ratios (MHR and LDL-C/HDL-C) were compared in univariate and multivariate analyses. After adjusting for confounding factors, our results suggested a possible better prediction ability for NHR levels in long-term clinical outcomes, compared with MHR and LDL-C/HDL-C.

From our analysis, we attempted to explain the result that higher NHR was associated with poorer clinical outcomes. Neutrophil was an indispensable component participating in the immuno-inflammatory response of AMI \[[@CR33], [@CR34]\]. An increase in neutrophil has been verified at the site of coronary lesion \[[@CR35]\]. Recent evidences indicated that elevated level of myeloperoxidase from the neutrophil could give rise to coronary atherosclerosis \[[@CR36], [@CR37]\]. Yunoki et al. pointed out that plasma myeloperoxidase levels were inversely correlated with HDL-C and serum paraoxonase-1 (PON-1) concentrations and activities \[[@CR38]\]. It was supposed that the interaction between myeloperoxidase and HDL-C in the circulation may decrease serum PON-1 levels. Besides, Park et al. reported that the risk of cardiovascular death and RMI appeared higher in the patients with lower level of HDL-C level \[[@CR39]\]. Previous studies showed that HDL-C was engaged in the inhibition of the inflammation and oxidation \[[@CR40], [@CR41]\]. According to the Murphy's study, the ability of HDL-C to inhibit neutrophils activation, attachment, diffusion, and migration might be related to the abundance of lipid rafts \[[@CR16]\].

Above all, because of the interaction of increased neutrophils and decreased HDL-C in AMI, an elevated NHR might be related to the inflammatory activity and the abnormal lipids metabolism. Besides, as for the complex interactions between neutrophil and HDL-C, the combined indicator of NHR might be more reliable than single parameter. That was consistent with the results from the present study. On top of all, as a new predictor for the prognosis of AMI patient, NHR could be calculated from the complete blood count on admission, which is quick and convenient.

Gensini score was an indicator to evaluate the severity of coronary artery disease \[[@CR42]\]. Specifically, different weight coefficients were assigned to different coronary artery branches according to their severity, which was conducive to reflect the severity of the disease objectively. Based on our results, NHR was positively correlated with Gensini score and was an effective predictive factor for long-term clinical outcomes. The combined application of the NHR and Gensini score might be more helpful for clinicians to identify the high-risk patients with AMI. Further studies are needed to validate this hypothesis.

We have to acknowledge that there were some limitations in this study. First, the retrospective design of the study sets a limit to the convincement of our study. Secondly, we could not compare the lipid ratios with other conventional inflammatory markers, for instance, C-reactive protein, fibrinogen, or myeloperoxidase. Because they were not routinely obtained in our study population. Thirdly, the patients were admitted with AMI within one month of symptom onset. Thus, the neutrophil level might not be static across this period of time. Lastly, our results did not show the well established link between diabetes and mortality. It might be because of the differences in sample size, study design, population selection, statistical method, outcome measurement and so on.

Conclusion {#Sec15}
==========

In summary, we observed that NHR might has a predictive value for prognosis in the long-term mortality and RMI of elderly AMI patients, which is superior to both MHR and LDL-C/HDL-C.

AMI

:   Acute myocardial infarction

HDL-C

:   High-density lipoprotein cholesterol

NHR

:   Neutrophil to high-density lipoprotein cholesterol ratio

MHR

:   Monocyte to high-density lipoprotein cholesterol ratio

LDL-C

:   Low-density lipoprotein cholesterol

LDL-C/HDL-C

:   Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

ROC

:   Receiver operating characteristic

RMI

:   Recurrent myocardial infarction

CAD

:   Coronary artery disease

STEMI

:   ST-segment elevation myocardial infarction

NSTEMI

:   Non-ST-elevation myocardial infarction

WBC

:   White blood cell

LVEF

:   Left ventricular ejection fraction

CAG

:   Coronary angiography

PCI

:   Percutaneous coronary intervention

CABG

:   Coronary artery bypass grafting

TIMI

:   Thrombolysis in myocardial infarction

AUC

:   Area under the curve

CI

:   Confidence interval

HR

:   Hazard ratio

PON-1

:   Paraoxonase-1
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